Publication at First Faculty of Medicine |
2017
Abstract
Psoriatic arthritis (PsA) is a chronic autoimmune disease affecting musculoskeletal system and skin that markedly influences the quality of life in patients according to its severity. Two large trials, FUTURE 1 and FUTURE 2, showed adequate efficacy of secukinumab, including satisfactory safety profile and self-reported efficacy end points of the therapy using standardized questionnaires.
Secukinumab became the first monoclonal antibody against interleukin 17A introduced into clinical practice in the setting of PsA.